Comment on “Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis”

• References

• 1 Dhainaut JF, Betty Yan S, Benjamin D. et al. Drotrecogin Alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-53.
• 2 Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31: S85-S93.
• 3 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of human activated protein C for treatment of patients with severe sepsis. N Engl J Med 2001; 344: 699-709.
• 4 Taylor Jr FB. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: Examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001; 29: S78-S89.
• 5 Minnema MC, Chang ACK, Jansen PM. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with E. coli. Blood 2000; 95: 1117-23.
• 6 Creasey AA, Chang ACK, Fiegen L. et al. Tissue factor pathway inhibitor (TFPI) reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-60.
• 7 Joyce DE, Gelbert L, Ciaccia A. et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11119-203.
• 8 Taylor Jr FB. Response of anticoagulant pathways in disseminated intravascular coagulation. Sem Thromb Haemost 2001; 27: 619-31.
• 9 Vincent JL, Angus DC, Artigas A. et al. Effects of Drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31: 834-40.
• 10 Abraham E, Arcaroli J, Carmody A. et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-4.